Theriva Biologics Q1 FY26 net loss narrows to $2 million; revenue rises to $300,000

Theriva Biologics, Inc.

Theriva Biologics, Inc.

TOVX

0.00
  • Theriva Biologics posted a net loss attributable to common stockholders of USD 2.04 million, narrowing from USD 4.32 million a year earlier.
  • Revenue was USD 300,000 versus no revenue a year earlier, while operating loss narrowed to USD 2.13 million from USD 4.42 million.
  • Research and development expense fell 88% to USD 355,000, while general and administrative expense rose 43% to USD 2.07 million.
  • Cash and cash equivalents rose to USD 14.4 million, with cash runway expected into Q1 2027.
  • Management said it aligned with FDA on key elements of a Phase 3 VCN-01 trial design in metastatic pancreatic ductal adenocarcinoma, with a dosing-feasibility study expected to start at a single site in Spain in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605051630PRIMZONEFULLFEED9713737) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.